<!doctype html> <html> <head><style>
             table { border-collapse: collapse; }
             th, td {
               word-wrap: break-word;
               max-width: 100%;
               font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
               border-bottom: 1px solid #ddd;
               padding: 5px;
               text-align: left;
             }
            tr:hover {background: #f4f4f4;}
            tr:hover .highlighted {background: repeating-linear-gradient(
                    45deg,
                    #ffff99,
                    #ffff99 10px,
                    #f4f4f4 10px,
                    #f4f4f4 20px
                  );}
           .highlighted { background-color: #ffff99; }
          </style></head><body><h2>Herpes simplex research</h2><br> <b>Section Title</b>: Vaccine candidates <br><b>Table Section Text</b>: The chart below is an attempt to list all known proposed HSV and VZV vaccines and their characteristics. As of 2019, there are no HSV vaccines in production. <br> <table>
<tr> <th colspan=1 rowspan=1 > Vaccine </th><th colspan=1 rowspan=1 > Company & Lead Researcher </th><th colspan=1 rowspan=1 > Vaccine Type </th><th colspan=1 rowspan=1 > Status </th><th colspan=1 rowspan=1 > Trial Results </th></tr>
<tr> <th colspan=1 rowspan=1 > Zostavax (VZV, shingles) </th><td colspan=1 rowspan=1 > Merck & Co. </td><td colspan=1 rowspan=1 > Live-attenuated. This is primarily a vaccine focusing on Varicella zoster virus, not Herpes simplex virus. </td><td colspan=1 rowspan=1 > In Production </td><td colspan=1 rowspan=1 > Vaccination showed an immune response of 70% in 50 years old adults. The effectiveness went down to approx 64% in 60 years old, 41% in 70 years old, and 18% in 80 years old individuals. </td></tr>
<tr> <th colspan=1 rowspan=1 > Varivax, Varilrix(Varicella, C.Pox) </th><td colspan=1 rowspan=1 > Merck & Co. & GlaxoSmithKline </td><td colspan=1 rowspan=1 > Live-attenuated. This is primarily a vaccine focusing on Varicella zoster virus, not Herpes simplex virus. </td><td colspan=1 rowspan=1 > In Production </td><td colspan=1 rowspan=1 > One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. </td></tr>
<tr> <th colspan=1 rowspan=1 > Shingrix, GSK1437173A (VZV, shingles) </th><td colspan=1 rowspan=1 > GlaxoSmithKline </td><td colspan=1 rowspan=1 > Subunit gE with AS01B/QS-21 adjuvant system. This is primarily a vaccine against Varicella zoster virus, not Herpes simplex virus. </td><td colspan=1 rowspan=1 > In Production </td><td colspan=1 rowspan=1 > Strong immune response in adults 65 and older. Final trials results reported an effectiveness of 90% in the first year, which went down slightly to 88% four years after vaccination. </td></tr>
<tr> <th colspan=1 rowspan=1 > Admedus HSV-2 therapeutic vaccine </th><td colspan=1 rowspan=1 > Admedus Ian Frazer </td><td colspan=1 rowspan=1 > DNA vaccine </td><td colspan=1 rowspan=1 > Phase II </td><td colspan=1 rowspan=1 > 58% reduction in viral shedding, 81% reduction in outbreaks (post-booster). The booster further reduced outbreaks and shedding. </td></tr>
<tr> <th class="highlighted"  colspan=1 rowspan=1 > dl5-29 / ACAM-529 / HSV-529 </th><td colspan=1 rowspan=1 > Sanofi Pasteur David Knipe </td><td class="highlighted"  colspan=1 rowspan=1 > HSV-2 replication-defective vaccine with UL5 and UL29 deleted </td><td colspan=1 rowspan=1 > Phase I </td><td colspan=1 rowspan=1 > HSV529 was safe, well-tolerated, immunogenic, eliciting significant neutralizing gD and ADCC-mediating antibodies. Modest cellular immune responses were observed only in HSV seronegative individuals. </td></tr>
<tr> <th colspan=1 rowspan=1 > VC2 </th><td colspan=1 rowspan=1 > Louisiana State University Gus Kousoulas </td><td colspan=1 rowspan=1 > Live-attenuated HSV vaccine with small deletions in UL20 and UL53 </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > The VC2 vaccine prevents HSV infection of neuronal axons and establishment of latency in animal models such as mice, guinea pig and rhesus monkeys. </td></tr>
<tr> <th colspan=1 rowspan=1 > R2 </th><td colspan=1 rowspan=1 > Thyreos LLC Gregory Smith, Gary Pickard, Ekaterina Heldwein </td><td colspan=1 rowspan=1 > Live-attenuated HSV vaccine mutated in R2 coding region of UL37 </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > A single-dose vaccine effective in mice and rats against multiple neuroinvasive herpesviruses including HSV. </td></tr>
<tr> <th colspan=1 rowspan=1 > HSV-2 ΔgD-2 </th><td colspan=1 rowspan=1 > Albert Einstein College of Medicine William Jacobs Jr & Betsy Harold </td><td colspan=1 rowspan=1 > Live-attenuated HSV-2 vaccine with US6 (gD) deleted </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > Combats HSV-1 & HSV-2 in mice </td></tr>
<tr> <th colspan=1 rowspan=1 > HSV-2 Trivalent Vaccine </th><td colspan=1 rowspan=1 > Perelman School of Medicine at the University of Pennsylvania Harvey Friedman & Sita Awasthi </td><td colspan=1 rowspan=1 > HSV-2 subunit trivalent vaccine (containing gC2, gD2, gE2) </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > Reduced shedding to 0.2% in animals </td></tr>
<tr> <th colspan=1 rowspan=1 > G103 </th><td colspan=1 rowspan=1 > Immune Design </td><td colspan=1 rowspan=1 > HSV-2 subunit trivalent vaccine (containing gD, pUL19, pUL25) </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > Prophylactic immunization completely protected against lethal intravaginal HSV-2 infection in mice </td></tr>
<tr> <th colspan=1 rowspan=1 > GV2207 </th><td colspan=1 rowspan=1 > GenVec </td><td colspan=1 rowspan=1 > ? </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > ? </td></tr>
<tr> <th colspan=1 rowspan=1 > NE-HSV2 </th><td colspan=1 rowspan=1 > NanoBio </td><td colspan=1 rowspan=1 > ? </td><td colspan=1 rowspan=1 > Preclinical </td><td colspan=1 rowspan=1 > ? </td></tr>
<tr> <th colspan=1 rowspan=1 > TBA </th><td colspan=1 rowspan=1 > Profectus BioSciences </td><td colspan=1 rowspan=1 > DNA vaccine </td><td colspan=1 rowspan=1 > Antigen Discovery Stage </td><td colspan=1 rowspan=1 > N/A </td></tr>
<tr> <th colspan=1 rowspan=1 > HSV-2 ICP0‾ HSV-2 0ΔNLS </th><td colspan=1 rowspan=1 > Rational Vaccines RVx William Halford </td><td colspan=1 rowspan=1 > Live-attenuated vaccine </td><td colspan=1 rowspan=1 > Embroiled in patient consent controversy. </td><td colspan=1 rowspan=1 > 65% of the patients reported being free of symptoms. </td></tr>
<tr> <th colspan=1 rowspan=1 > Vitaherpavac & Herpovax </th><td colspan=1 rowspan=1 > Russia </td><td colspan=1 rowspan=1 > ? </td><td colspan=1 rowspan=1 > ? </td><td colspan=1 rowspan=1 > ? </td></tr>
</table> <br> <h3>Sentence(s)</h3>1. The dl5-29 vaccine is also known under the name ACAM-529 or HSV-529, which is a replication-defective vaccine. <br> <br><br><b>Categories:</b><br><b>Numerical:</b> Uses math skills for writing the sentence. Uses math operations (addition, subtraction, average, etc.), counting numbers, frequency of items, etc.<br> <b>Commonsense:</b> Uses commonsene knowledge about situations humans encounter in everyday life – physical objects, word meanings, social or physical domains, peoples' intentions, etc.<br> <b>Temporal:</b> When concepts related to time and temporal aspects are required for writing the sentence. Duration, ordering, typical time of events, time differences between events.<br> <b>Table:</b> Writing the sentence requires knowledge from the table except: the highlighted cells, row and column headers, table titles, section titles, section texts.<br> <b>Out of Table:</b> Writing the sentence requires external knowledge that is not present in the table nor common sense. Knowledge about some specific domain comes under this category. </body></html>
